MEDIUM confidence: 100% data completeness, but the composite (59) sits in the indecisive 30–70 range — strong-buy and short calls require a more decisive composite. What does confidence mean?
Technical context for active traders — derived from price, the 50/200-day moving averages, the 52-week range, and recent volume. Not part of the QScore.
Fama-French 5-factor (2×3) + Momentum, monthly OLS with Newey-West errors. Bars show signed factor betas; faded bars/figures aren't statistically significant.
Avg target $107 (last qtr, 3 analysts) → $100 (last mo, 1) (-6.3%).
Buy-rated share 73% → 69% over ~3 months (-4pp).
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| May 2026 | $0.92 | $1.12 | +21.7% |
| Feb 2026 | $1.06 | $1.28 | +20.8% |
| Nov 2025 | $0.78 | $1.18 | +51.1% |
| Aug 2025 | $0.76 | $0.86 | +13.2% |
| May 2025 | $0.74 | $0.68 | -8.6% |
| Feb 2025 | $0.74 | $0.84 | +13.5% |
| Nov 2024 | $0.65 | $0.83 | +28.3% |
| Aug 2024 | $0.68 | $0.75 | +10.3% |
| Metric (USD) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $958M— | $1.0B+6.8% | $1.6B+53.3% | $2.5B+60.6% | $2.9B+16.7% |
| EPS (dil.) | $1.44— | $1.85+28.5% | $1.07-42.2% | $0.75-29.9% | $3.92+422.7% |
| Free Cash Flow | $219M— | $104M-52.4% | $165M+58.2% | $405M+145.2% | $589M+45.3% |
| Gross Margin | 75.0% | 74.2%-0.8pp | 65.1%-9.2pp | 58.9%-6.2pp | 67.4%+8.5pp |
| Operating Margin | 17.9% | 22.3%+4.3pp | 8.5%-13.8pp | 6.6%-1.9pp | 16.3%+9.7pp |
| Net Margin | 15.6% | 18.6%+3.0pp | 7.8%-10.8pp | 4.1%-3.7pp | 18.3%+14.2pp |
Absolute figures with year-over-year change. Margins show the level with the change in percentage points (pp). “n/m” = not meaningful (prior ≤ 0); ⚠ marks a large percentage off a small base — read the dollar figure.
Net insider -$5.4M over 180 days (0 open-market buys, 5 sells). Insider buying is the informative signal; routine selling is normal.
Short interest, days-to-cover, and institutional-ownership change require a data-plan upgrade (not yet available).
Forward-return IC, quintile spread & hit rate publish on /performance as the tracking panel accrues enough no-look-ahead history.
Net buyback (repurchases less issuance) ÷ market cap, plus trailing dividend yield.
The QScore of 59 for Globus Medical indicates a moderately favorable outlook, driven by strong growth scores, with revenue and EPS growth of 16.7% and 423.7%, respectively. The stock's value score is somewhat lower, reflecting a P/E of 19.8, which is relatively in line with industry peers. The short-term and long-term scores are closely aligned, suggesting a consistent view of the company's prospects, with momentum and profitability scores also contributing to the overall assessment, exhibiting strong revenue growth and a gross margin near 68%.